Pneumotox » Drug » Cetuximab

Cetuximab

4

Separating cetuximab- vs. chemotherapy-related ILD can be problematic except when drug used as a solo agent (PMID 20975380)

Last update : 02/01/2020

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1

I.b Pneumonitis (ILD)

1

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

1

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

1

II.b ARDS - Acute lung injury

1

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

2

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

3

XII.m Cardiac- cardiorespiratory/pulmonary arrest

1

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

1

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist